Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73.1M | $113M | $155M | $189M | $242M | $276M | $296M | $307M | $311M |
| Revenue growth | — | 54.0% | 37.6% | 21.9% | 28.1% | 14.2% | 7.1% | 3.6% | 1.5% |
| Operating income | -$45.5M | -$60.1M | -$54.9M | -$96.1M | -$144M | -$140M | -$127M | -$69.8M | -$161M |
| Operating margin | -62.3% | -53.4% | -35.4% | -50.9% | -59.4% | -50.7% | -42.9% | -22.8% | -51.7% |
| Net income | -$47.0M | -$62.0M | -$60.1M | -$115M | -$153M | -$137M | -$118M | -$69.5M | -$178M |
| Net margin | -64.4% | -55.1% | -38.8% | -60.9% | -63.3% | -49.7% | -39.9% | -22.7% | -57.2% |
| EPS (diluted) | -$12.13 | -$23.76 | -$12.86 | -$2.91 | -$3.23 | -$2.63 | -$2.09 | -$1.15 | -$2.55 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$36.8M | -$40.3M | -$32.2M | -$26.1M | -$23.1M | -$35.3M | -$33.1M | $14.6M | $731K |
| Capital expenditures | $2.47M | $2.08M | $2.02M | $7.78M | $10.4M | $2.17M | $1.24M | $1.62M | $968K |
| Free cash flow | -$39.3M | -$42.4M | -$34.2M | -$33.9M | -$33.6M | -$37.4M | -$34.3M | $12.9M | -$237K |
| Share buybacks | $0.00 | $8.71M | $0.00 | $0.00 | $0.00 | $8.39M | $1.81M | $0.00 | $5.00M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $23.0M | $28.4M | $18.0M | $92.0M | $193M | $116M | $106M | $250M | $50.8M |
| Total assets | — | $111M | $302M | $578M | $832M | $752M | $702M | $859M | $503M |
| Total liabilities | — | $75.9M | $102M | $302M | $310M | $327M | $335M | $494M | $257M |
| Long-term debt | — | $18.8M | $48.2M | $169M | $181M | $227M | $228M | $151M | $152M |
| Shareholders' equity | -$259M | -$375M | $201M | $276M | $522M | $425M | $367M | $365M | $246M |
| Retained earnings | — | -$375M | -$611M | -$726M | -$879M | -$999M | -$1.12B | -$1.19B | -$1.36B |
| Shares (wtd avg diluted) | — | — | 18.7M | 39.5M | 47.5M | 54.1M | 56.4M | 60.2M | 69.9M |
Every figure is extracted from Health Catalyst, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.